These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1030 related articles for article (PubMed ID: 33147606)
1. Brigatinib and lorlatinib: their effect on ALK inhibitors in NSCLC focusing on resistant mutations and central nervous system metastases. Naito T; Shiraishi H; Fujiwara Y Jpn J Clin Oncol; 2021 Jan; 51(1):37-44. PubMed ID: 33147606 [TBL] [Abstract][Full Text] [Related]
2. Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study. Solomon BJ; Besse B; Bauer TM; Felip E; Soo RA; Camidge DR; Chiari R; Bearz A; Lin CC; Gadgeel SM; Riely GJ; Tan EH; Seto T; James LP; Clancy JS; Abbattista A; Martini JF; Chen J; Peltz G; Thurm H; Ou SI; Shaw AT Lancet Oncol; 2018 Dec; 19(12):1654-1667. PubMed ID: 30413378 [TBL] [Abstract][Full Text] [Related]
3. Management of Central Nervous System Metastases in Patients With Advanced Anaplastic Lymphoma Kinase-Rearranged Non-Small-Cell Lung Cancer During Crizotinib Treatment. Zhao Y; Zhang B; Wang S; Qiao R; Xu J; Zhang L; Zhang Y; Han B Clin Lung Cancer; 2019 Nov; 20(6):e631-e637. PubMed ID: 31362880 [TBL] [Abstract][Full Text] [Related]
4. Lorlatinib Salvages CNS Relapse in an ALK-Positive Non-Small-Cell Lung Cancer Patient Previously Treated With Crizotinib and High-Dose Brigatinib. Sakamoto MR; Honce JM; Lindquist DL; Camidge DR Clin Lung Cancer; 2019 Mar; 20(2):e133-e136. PubMed ID: 30578110 [No Abstract] [Full Text] [Related]
5. Lorlatinib for the treatment of anaplastic lymphoma kinase-positive non-small cell lung cancer. Yang J; Gong W Expert Rev Clin Pharmacol; 2019 Mar; 12(3):173-178. PubMed ID: 30657349 [TBL] [Abstract][Full Text] [Related]
6. Brigatinib vs alectinib in crizotinib-resistant advanced anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALTA-3). Popat S; Liu G; Lu S; Song G; Ma X; Yang JC Future Oncol; 2021 Nov; 17(32):4237-4247. PubMed ID: 34423676 [TBL] [Abstract][Full Text] [Related]
7. Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer. Camidge DR; Kim HR; Ahn MJ; Yang JC; Han JY; Lee JS; Hochmair MJ; Li JY; Chang GC; Lee KH; Gridelli C; Delmonte A; Garcia Campelo R; Kim DW; Bearz A; Griesinger F; Morabito A; Felip E; Califano R; Ghosh S; Spira A; Gettinger SN; Tiseo M; Gupta N; Haney J; Kerstein D; Popat S N Engl J Med; 2018 Nov; 379(21):2027-2039. PubMed ID: 30280657 [TBL] [Abstract][Full Text] [Related]
8. Shaw AT; Solomon BJ; Besse B; Bauer TM; Lin CC; Soo RA; Riely GJ; Ou SI; Clancy JS; Li S; Abbattista A; Thurm H; Satouchi M; Camidge DR; Kao S; Chiari R; Gadgeel SM; Felip E; Martini JF J Clin Oncol; 2019 Jun; 37(16):1370-1379. PubMed ID: 30892989 [TBL] [Abstract][Full Text] [Related]
9. Brigatinib versus crizotinib for ALK-positive NSCLC. Stirrups R Lancet Oncol; 2018 Nov; 19(11):e585. PubMed ID: 30293790 [No Abstract] [Full Text] [Related]
10. Resistance profiles of anaplastic lymphoma kinase tyrosine kinase inhibitors in advanced non-small-cell lung cancer: a multicenter study using targeted next-generation sequencing. Lin YT; Chiang CL; Hung JY; Lee MH; Su WC; Wu SY; Wei YF; Lee KY; Tseng YH; Su J; Chung HP; Lin CB; Ku WH; Chiang TS; Chiu CH; Shih JY Eur J Cancer; 2021 Oct; 156():1-11. PubMed ID: 34392186 [TBL] [Abstract][Full Text] [Related]
11. Inflammation-related molecular signatures involved in the anticancer activities of brigatinib as well as the prognosis of EML4-ALK lung adenocarcinoma patient. Ge FJ; Dai XY; Qiu Y; Liu XN; Zeng CM; Xu XY; Chen YD; Zhu H; He QJ; Gai RH; Ma SL; Chen XQ; Yang B Acta Pharmacol Sin; 2024 Jun; 45(6):1252-1263. PubMed ID: 38360931 [TBL] [Abstract][Full Text] [Related]
12. Brigatinib Versus Crizotinib in Advanced ALK Inhibitor-Naive ALK-Positive Non-Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial. Camidge DR; Kim HR; Ahn MJ; Yang JCH; Han JY; Hochmair MJ; Lee KH; Delmonte A; García Campelo MR; Kim DW; Griesinger F; Felip E; Califano R; Spira A; Gettinger SN; Tiseo M; Lin HM; Gupta N; Hanley MJ; Ni Q; Zhang P; Popat S J Clin Oncol; 2020 Nov; 38(31):3592-3603. PubMed ID: 32780660 [TBL] [Abstract][Full Text] [Related]
13. Cost‑Effectiveness of Lorlatinib in First-Line Treatment of Adult Patients with Anaplastic Lymphoma Kinase (ALK)‑Positive Non‑Small‑Cell Lung Cancer in Sweden. Naik J; Beavers N; Nilsson FOL; Iadeluca L; Lowry C Appl Health Econ Health Policy; 2023 Jul; 21(4):661-672. PubMed ID: 37173513 [TBL] [Abstract][Full Text] [Related]
14. An evaluation of brigatinib as a promising treatment option for non-small cell lung cancer. Hamilton G; Hochmair MJ Expert Opin Pharmacother; 2019 Sep; 20(13):1551-1561. PubMed ID: 31328968 [No Abstract] [Full Text] [Related]
16. The accelerated path of ceritinib: Translating pre-clinical development into clinical efficacy. Mok TSK; Crino L; Felip E; Salgia R; De Pas T; Tan DSW; Chow LQM Cancer Treat Rev; 2017 Apr; 55():181-189. PubMed ID: 28427013 [TBL] [Abstract][Full Text] [Related]
17. Intracranial remission with brigatinib rechallenge as fifth-line ALK inhibition therapy in a lung cancer patient. Hochmair M; Weinlinger C; Prosch H Anticancer Drugs; 2019 Nov; 30(10):1058-1060. PubMed ID: 31033499 [TBL] [Abstract][Full Text] [Related]
18. Exploratory Analysis of Brigatinib Activity in Patients With Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer and Brain Metastases in Two Clinical Trials. Camidge DR; Kim DW; Tiseo M; Langer CJ; Ahn MJ; Shaw AT; Huber RM; Hochmair MJ; Lee DH; Bazhenova LA; Gold KA; Ou SI; West HL; Reichmann W; Haney J; Clackson T; Kerstein D; Gettinger SN J Clin Oncol; 2018 Sep; 36(26):2693-2701. PubMed ID: 29768119 [TBL] [Abstract][Full Text] [Related]
19. Pharmacological and clinical properties of lorlatinib in the treatment of El Darsa H; Abdel-Rahman O; Sangha R Expert Opin Pharmacother; 2020 Sep; 21(13):1547-1554. PubMed ID: 32511029 [TBL] [Abstract][Full Text] [Related]
20. Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial. Gettinger SN; Bazhenova LA; Langer CJ; Salgia R; Gold KA; Rosell R; Shaw AT; Weiss GJ; Tugnait M; Narasimhan NI; Dorer DJ; Kerstein D; Rivera VM; Clackson T; Haluska FG; Camidge DR Lancet Oncol; 2016 Dec; 17(12):1683-1696. PubMed ID: 27836716 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]